Industry Overview - Regenerative medicine (RM) utilizes biological and engineering theories to promote self-repair and regeneration of the body, or to construct new tissues and organs for repairing, regenerating, and replacing damaged tissues and organs [1][4] - The global regenerative medicine market is expanding, with the market size projected to grow from $20.04 billion in 2021 to $35.82 billion in 2024 [1][12] Market Status - Regenerative medicine is considered the "third medical revolution" following drug and surgical treatments, becoming a core component of life science strategies globally [6][12] - The industry includes upstream raw materials and equipment supply, midstream product R&D and production, and downstream application through medical institutions and aesthetic organizations [4][12] Policy and Regulatory Environment - Various countries have implemented policies to promote the development of regenerative medicine, such as the U.S. "21st Century Cures Act" and the EU's regulations on biotechnology [7][9] - In China, policies have been established to support the clinical application of regenerative medicine technologies, including the management of stem cell therapies and the promotion of innovative medical technologies [9][23] Market Competition - The regenerative medicine sector has attracted numerous companies, with major players including Johnson & Johnson, Bard, Geistlich, and domestic firms like Zhenghai Biological, Guanhou Biological, and Maipu Medical [16][18] - The market is characterized by a diverse range of products and applications, with companies focusing on specific therapeutic areas such as cancer treatment, tissue repair, and organ transplantation [18][20] Development Trends - The industry is witnessing technological integration and innovation, with advancements in 3D bioprinting, gene editing, and artificial intelligence enhancing treatment efficacy [22][24] - The dual drive of policy support and capital investment is accelerating the commercialization of regenerative medicine, with increasing coverage of medical insurance for regenerative products [23][24]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 随着全球科技的不断进步，医疗器械创新的步伐也在加快。根据美国的统计数据， 70%的医疗器械创新想法 都来自于临床医生的实际经验和需求 。临床医 生不仅是治疗的执行者，也是医疗器械创新的重要推动者。 过去，许多一线城市的三甲医院的大专家们已经走在了创新的前沿，取得了显著的成果转化。而在更为广泛的地区，比如像东北地区，医工交叉仍然处于一 个萌芽阶段，充满了探索的机会与挑战。 亓明教授，作为大连医科大学附属第一医院血管外科的资深专家，正是这种医工交叉领域探索的代表之一 。思宇 MedTech记者近日专访了亓教授，探讨了他在这一领域的深刻思考与实践。 在血管外科工作超过20年的亓明教授，近年来开始逐渐对医工交叉领域产生了浓厚兴趣。对于他来说，这一转变并非偶然，而是基于长期的临床积累以及对 创新医疗器械需求的深刻理解。 一、为什么开始关注医工交叉？ 亓教授坦言，自己对医工交叉的兴趣源自三个主要原因。 第一，看到许多大专家们已经在尝试这个领域。 "最早，我接触临床时 ...